As such, the significance of being able to detect increases in CD8+ and CD2+ EVPs with HAM compared to HVs and MS patients in the CSF may go beyond a potential novel biomarker – it is possible that the EVPs themselves may play a role in HAM pathogenesis. The gene discussed is CD8A; the disease is myeloid sarcoma.